Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates

被引:78
|
作者
Boscarino, Joseph A. [1 ]
Hoffman, Stuart N. [1 ]
Han, John J. [2 ]
机构
[1] Geisinger Med Clin, Ctr Hlth Res, Danville, PA USA
[2] Geisinger Med Clin, Dept Pain Med, Danville, PA USA
来源
关键词
opioids; drug-use disorders; DSM-5; prescription drugs; pain; outpatients;
D O I
10.2147/SAR.S85667
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims: Previously, we estimated the prevalence and risk factors for prescription opioid-use disorder among outpatients on opioid therapy using the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 and DSM-4 criteria. However, at the time, the DSM-5 criteria were not finalized. In the current study, we analyzed these data using the final DSM-5 criteria and compared these results. Methods: Using electronic records from a large US health care system, we identified outpatients receiving five or more prescription orders for opioid therapy in the past 12 months for noncancer pain (mean prescription orders = 10.72; standard deviation = 4.96). In 2008, we completed diagnostic interviews with 705 of these patients using the DSM-4 criteria. In the current study, we reassessed these results using the final DSM-5 criteria. Results: The lifetime prevalence of DSM-5 opioid-use disorders using the final DSM-5 criteria was 58.7% for no or few symptoms (<2), 28.1% for mild symptoms (2-3), 9.7% for moderate symptoms (4-5), and 3.5% for severe symptoms (six or more). Thus, the lifetime prevalence of "any" prescription opioid-use disorder in this cohort was 41.3% (95% confidence interval [CI] = 37.6-45.0). A comparison to the DSM-4 criteria indicated that the majority of patients with lifetime DSM-4 opioid dependence were now classified as having mild opioid-use disorder, based on the DSM-5 criteria (53.6%; 95% CI = 44.1-62.8). In ordinal logistic regression predicting no/ few, mild, moderate, and severe opioid-use disorder, the best predictors were age <65 years, current pain impairment, trouble sleeping, suicidal thoughts, anxiety disorders, illicit drug use, and history of substance abuse treatment. Conclusion: Given the final DSM-5 criteria, including the elimination of tolerance and withdrawal, inclusion of craving and abuse symptoms, and introduction of a new graded severity classification, the prevalence of opioid-use disorders has changed, while many of the DSM-4 risk factors for opioid dependence were similar. To our knowledge, this is one of the first studies to compare the final results for DSM-5 versus DSM-4 prescription opioid-use disorders among a high-risk patient population.
引用
收藏
页码:83 / 91
页数:9
相关论文
共 50 条
  • [1] Prevalence of Prescription Opioid-Use Disorder Among Chronic Pain Patients: Comparison of the DSM-5 vs. DSM-4 Diagnostic Criteria
    Boscarino, Joseph A.
    Rukstalis, Margaret R.
    Hoffman, Stuart N.
    Han, John J.
    Erlich, Porat M.
    Ross, Stephen
    Gerhard, Glenn S.
    Stewart, Walter F.
    JOURNAL OF ADDICTIVE DISEASES, 2011, 30 (03) : 185 - 194
  • [2] Problematizing the DSM-5 criteria for opioid use disorder: A qualitative analysis
    Boyd, Susan
    Ivsins, Andrew
    Murray, Dave
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 78
  • [3] Medications for Opioid Use Disorder Among Patients With and Without Exposure to Long-term Opioid Therapy for Chronic Pain
    Wyse, Jessica J.
    Lindner, Stephan
    Handley, Robert
    Morasco, Benjamin J.
    Carlson, Kathleen F.
    Gordon, Adam J.
    Lovejoy, Travis I.
    JOURNAL OF PAIN, 2024, 25 (04): : 71 - 71
  • [4] MEDICAL CANNABIS USE AND ALCOHOL USE DISORDER AMONG PATIENTS PRESCRIBED LONG-TERM OPIOID THERAPY
    Nugent, Shannon
    Yarborough, Bobbi Jo H.
    Smith, Ning
    Green, Carla A.
    Dobscha, S.
    Deyo, Richard
    Morasco, B.
    ANNALS OF BEHAVIORAL MEDICINE, 2017, 51 : S842 - S843
  • [5] Association of opioid dose reduction with opioid overdose and opioid use disorder among patients on high-dose long-term opioid therapy in North Carolina
    DiPrete, Bethany
    Ranapurwala, Shabbar
    Maierhofer, Courtney
    Fulcher, Naoko
    Chelminski, Paul
    Ringwalt, Christopher
    Ives, Timothy
    Dasgupta, Nabarun
    Go, Vivian
    Pence, Brian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 50 - 50
  • [6] Transdiagnostic factors predicting prescription opioid-use disorder severity: A 12-month prospective study in patients on long-term opioid therapy for chronic pain
    Rodriguez-Espinosa, Sara
    Coloma-Carmona, Ainhoa
    Perez-Carbonell, Ana
    Roman-Quiles, Jose Francisco
    Carballo, Jose Luis
    DRUG AND ALCOHOL DEPENDENCE, 2025, 266
  • [7] Prescription stimulant use during long-term opioid therapy and risk for opioid use disorder
    Scherrer, Jeffrey F.
    Salas, Joanne
    Grucza, Richard
    Wilens, Timothy
    Quinn, Patrick D.
    Sullivan, Mark D.
    Rossom, Rebecca C.
    Wright, Eric
    Piper, Brian
    Sanchez, Katherine
    Lapham, Gwen
    DRUG AND ALCOHOL DEPENDENCE REPORTS, 2022, 5
  • [8] Patterns and correlates of medical cannabis use for pain among patients prescribed long-term opioid therapy
    Nugent, Shannon M.
    Yarborough, Bobbi Jo
    Smith, Ning X.
    Dobscha, Steven K.
    Deyo, Richard A.
    Green, Carla A.
    Morasco, Benjamin J.
    GENERAL HOSPITAL PSYCHIATRY, 2018, 50 : 104 - 110
  • [9] DSM-5 Alcohol Use Disorder Severity in Puerto Rico: Prevalence, Criteria Profile, and Correlates
    Caetano, Raul
    Gruenewald, Paul
    Vaeth, Patrice A. C.
    Canino, Glorisa
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 (02): : 378 - 386
  • [10] Association of Opioid Dose Reduction With Opioid Overdose and Opioid Use Disorder Among Patients Receiving High-Dose, Long-term Opioid Therapy in North Carolina
    DiPrete, Bethany L.
    Ranapurwala, Shabbar, I
    Maierhofer, Courtney N.
    Fulcher, Naoko
    Chelminski, Paul R.
    Ringwalt, Christopher L.
    Ives, Timothy J.
    Dasgupta, Nabarun
    Go, Vivian F.
    Pence, Brian W.
    JAMA NETWORK OPEN, 2022, 5 (04) : E229191